That's a 3.5Million people market in US unpartnered which is the most lucrative. And they get 545M $ in milestones.
Rest of the world, Mid 20's royalty and 50-50 development costs where the drug pricing has lots of if's n but's is not bad at all.
All in all, I feel it is a wonderful deal for Vertex. I feel Novartis bungled up with all of it's deals in Hcv space. It missed the bus in Vertex's case.
Market Data 
Markets 
AI
